Oral Dosage Form New Animal Drugs; Milbemycin Oxime/Lufenuron Tablets

摘要

The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a new animal drug application (NADA) filed by Novartis Animal Health US, Inc. The NADA provides for use of milbemycin oxime/lufenuron tablets for prevention of heartworm disease caused by Dirofilaria immitis, control of adult Ancylostoma caninum, the removal and control of adult Toxocara canis, Toxascaris leonina, and Trichuris vulpis infections, and the prevention and control of flea populations in dogs.